z-logo
open-access-imgOpen Access
Antiplatelet drugs, anticoagulants and elective surgery
Author(s) -
Eileen Merriman,
Huyen Tran
Publication year - 2011
Publication title -
australian prescriber
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.735
H-Index - 26
eISSN - 1839-3942
pISSN - 0312-8008
DOI - 10.18773/austprescr.2011.074
Subject(s) - medicine , warfarin , clopidogrel , aspirin , anticoagulant , coronary stent , heparin , thrombosis , elective surgery , antithrombotic , surgery , stent , cardiology , atrial fibrillation , restenosis
Summary There is an increased risk of bleeding when patients taking anticoagulant or antiplatelet drugs require surgery. This risk must be balanced against the risk of harm if treatment is stopped. For many minor procedures aspirin or warfarin can be continued. patients having non-cardiac surgery may be able to continue aspirin, but clopidogrel should be stopped unless there is a high risk of thrombosis. patients taking warfarin may require bridging anticoagulation around the time of major surgery. This involves replacing the warfarin with unfractionated or low molecular weight heparin. Consultation with a cardiologist is particularly recommended if a patient with a coronary stent requires surgery.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom